# Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

> **NCT01712074** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 186 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** PF-05212377 (SAM-760)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01712074
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 186 (ACTUAL)
- **Why stopped:** The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria were met. The termination was not due to safety concerns.
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712074, "Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01712074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*